Niosomal encapsulation of the antitubercular drug, pyrazinamide

References

• Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. (2006). The resumption of consumption− a review on tuberculosis. Mem Inst Oswaldo Cruz, 101:697–714.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2007). WHO report 2007: Global tuberculosis control.
   Google Scholar
• Elston JW, Thaker HK. (2008). Co-infection with human immunodeficiency virus and tuberculosis. Indian J Dermatol Venereol Leprol, 74:194–199.
   PubMed Web of Science ®Google Scholar
• Mitchison DA. (1985). The action of antituberculosis drugs in short-course chemotherapy. Tubercle, 66:219–225.
   PubMedGoogle Scholar
• Zhang Y, Mitchison D. (2003). The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis, 7:6–21.
   PubMed Web of Science ®Google Scholar
• Heifets L, Lindholm-Levy P. (1992). Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis, 145:1223–1225.
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Florence AT. (1995). Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Coll Interface Sci, 58:1–55.
   Web of Science ®Google Scholar
• Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. (1985). The preparation and properties of niosomes–non-ionic surfactant vesicles. J Pharm Pharmacol, 37:863–868.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Dolan TF, Coombs GH, Baillie AJ. (1988). Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol, 40:161–165.
   PubMed Web of Science ®Google Scholar
• Namdeo A, Jain NK. (1996). Niosomes as drug carriers. Ind J Pharm Sci, 58:41–46.
   Google Scholar
• Baillie AJ, Coombs GH, Dolan TF, Laurie J. (1986). Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol, 38:502–505.
   PubMed Web of Science ®Google Scholar
• British pharmacopoeia. (2007). Pyrazinamide. Stationary office, London. pp. 2879.
   Google Scholar
• El-Ridy MS, Ammar HO, Ghorab M, Ghorab MM. (1994). Evaluation of the antischistosomal effect of praziquantel in a liposomal delivery system in mice. Int J Pharm, 103:237–241.
   Web of Science ®Google Scholar
• El-Ridy MS, Khalil RM, Moustafa DM, El-Rashdy MM, Osman A, Monem AS. (1997). Chemoprophylaxis of schistosomiasis using liposome encapsulated oxamniquine. Drug Dev Ind Pharm, 23:771–782.
   Web of Science ®Google Scholar
• El-Ridy MS, Mostafa DM, Abdel-Alim SH, Abdelbary A. (2006). Liposomal encapsulation of the tuberculocidal drug, pyrazinamide, for increasing safety and potency. Egypt Pharm J, 5:29–43.
   Google Scholar
• El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, Abd El-Alim S. (2007). Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm, 330:82–88.
   PubMed Web of Science ®Google Scholar
• Bangham AD, Horne RW. (1964). Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol, 8:660–668.
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. (2003). Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother, 52:981–986.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. (2004). Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother, 53:635–640.
   PubMed Web of Science ®Google Scholar
• Orozco LC, Quintana FO, Beltrán RM, de Moreno I, Wasserman M, Rodriguez G. (1986). The use of rifampicin and isoniazid entrapped in liposomes for the treatment of Murine tuberculosis. Tubercle, 67:91–97.
   PubMedGoogle Scholar
• Marks J. (1972). Ending the routine guinea-pig test. Tubercle, 53:31–34.
   PubMedGoogle Scholar
• Parisi AN, Antoine AD. (1975). Characterization of Bacillus pumilus E601 spores after single sublethal gamma irradiation treatments. Appl Microbiol, 29:34–39.
   PubMedGoogle Scholar
• Juliano RL, Stamp D. (1978). Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem Pharmacol, 27:21–27.
   PubMed Web of Science ®Google Scholar
• Cable C. (1989). An examination of the effects of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles. PhD Thesis, University of Strathclyde, Glasgow, UK.
   Google Scholar
• Junyaprasert VB, Teeranachaideekul V, Supaperm T. (2008). Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS Pharmscitech, 9:851–859.
   PubMed Web of Science ®Google Scholar
• Deol P, Khuller GK, Joshi K. (1997). Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother, 41:1211–1214.
   PubMed Web of Science ®Google Scholar
• Falk R, Randolph TW, Meyer JD, Kelly RM, Manning MC. (1997). Controlled release of ionic compounds from poly (L-lactide) microspheres produced by precipitation with a compressed antisolvent. J Contr Rel, 44:77–85.
   Web of Science ®Google Scholar
• Jain CP, Vyas SP. (1995). Preparation and characterization of niosomes containing rifampicin for lung targeting. J Microencapsul, 12:401–407.
   PubMed Web of Science ®Google Scholar
• Gaur PK, Mishra S, Gupta VB, Rathod MS, Purohit S, Savla BA. (2010). Targeted drug delivery of Rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome. Drug Dev Ind Pharm, 36:638–646.
   PubMed Web of Science ®Google Scholar
• Kamath MP, Shenoy BD, Tiwari SB, Karki R, Udupa N, Kotian M. (2000). Prolonged release biodegradable vesicular carriers for rifampicin–formulation and kinetics of release. Indian J Exp Biol, 38:113–118.
   PubMedGoogle Scholar
• Jain CP, Vyas SP, Dixit VK. (2006). Niosomal system for delivery of rifampicin to lymphatics. Ind J Pharm Sci, 68:575–578.
   Google Scholar